
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay is positioned for long-term success as its recent FDA approval of Neurolief’s Proliv™Rx system opens up opportunities for growth in both the at-home and in-clinic market segments. With a 12-month price target of $30 per share and a projected 12-month revenue of $60.4M, BrainsWay's valuation appears to be undervalued compared to other medtech companies. However, potential risks to consider include slower market uptake, difficulty in expanding reimbursement and market access, limitations in advancing into other indications, and a potential for long-term dilution.
Bears say
BrainsWay is facing several challenges that may make it difficult for the company to meet its ~$640M total firm value and $15 per share target. These risks include potential slow adoption of their Deep TMS systems, challenges in expanding reimbursement and market access, and potential difficulties in successfully advancing in new indications. Additionally, if BrainsWay faces long-term dilution risk, it could further impact their financials and overall outlook.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares